research Tyrosine Kinase Inhibitors: A Review on Pharmacology, Metabolism, and Side Effects
Tyrosine kinase inhibitors effectively treat cancers but often cause skin and other side effects.
Search
for
Sort by
Research
30 / 49 results
research The PDGF/PDGFR Pathway as a Drug Target
The PDGF/PDGFR pathway is a potential drug target with mixed success in treating various diseases, including some cancers and fibrosis.
research Unique Cutaneous Reaction to Second- and Third-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
Certain leukemia drugs can cause severe skin reactions that may require stopping treatment.
research Clinical Management of Cutaneous Adverse Events in Patients on Targeted Anticancer Therapies and Immunotherapies: A National Consensus Statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
Spanish experts provided guidelines for treating skin side effects in cancer patients on new therapies, stressing early action and teamwork.
research Adverse Cutaneous Reactions to the New Second-Generation Tyrosine Kinase Inhibitors (Dasatinib, Nilotinib) in Chronic Myeloid Leukemia
Many patients on new leukemia drugs had mild to moderate skin reactions.
research Tyrosine Kinase Inhibitors in Dermatology: A Systematic Review
Tyrosine kinase inhibitors show promise in treating some skin diseases but their definitive role in dermatology is still unclear.
research Keratosis Pilaris-Like Eruption During Chronic Myeloid Leukemia Treatment With Tyrosine Kinase Inhibitors: A Literature Review And Case Report On Imatinib
Some leukemia treatments can cause skin reactions similar to keratosis pilaris.
research Tyrosine Kinase Inhibitors Against Cancer: Their Safety in 216 Moroccan Patients
Tyrosine Kinase Inhibitors are effective against cancer but can cause skin, digestive, and blood side effects, including hair loss.
research Taiwanese Dermatological Association Consensus for the Prevention and Management of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Related Skin Toxicities
The guidelines help doctors manage skin problems from certain cancer treatments to improve patients' lives.
research Severe Scarring Alopecia Associated with Combinational Use of Ficlatuzumab and Gefitinib: A Clinical and Immunohistochemistry Study
Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.
research Management of Toxicities of Targeted Therapies
Targeted therapies for lung cancer are effective but require careful management of side effects to benefit patients.
research Target-Adverse Events and Fear of Cancer Progression, Anxiety, and Depression in Patients with Advanced Non-Small Cell Lung Cancer
Adverse events in lung cancer treatments increase fear, anxiety, and depression, with newer therapies causing fewer side effects.
research Dasatinib-Induced Leukotrichia in a Patient With Chronic Myelogenous Leukemia
A woman's hair turned white after taking a cancer drug called dasatinib.
research Nilotinib-Induced Generalized Keratosis Pilaris: Report of a Rare Case
Nilotinib can cause generalized keratosis pilaris.
research Forum
The document concludes that various medications and treatments can have significant, sometimes adverse, effects on health outcomes.
research Large-Scale Multicenter Prospective Registry Study of Ripretinib in Advanced GIST: A Real-World Study from China
Ripretinib is effective and safe for treating advanced GIST in Chinese patients, particularly for non-gastric GISTs.
research EGFR Inhibitors and Cutaneous Complications: A Practical Approach to Management
The document provides advice on how to recognize and treat skin-related side effects of cancer drugs known as EGFR inhibitors.
research Non-Rash Skin Toxicities Associated with Novel Targeted Therapies
Early recognition and management of skin side effects from new cancer therapies can prevent treatment delays.
research Chemotherapy-Induced Iatrogenic Injury of Skin: New Drugs and New Concepts
New chemotherapy drugs cause skin side effects, but treatments like minocycline and tetracycline can help reduce them.
research A Case of Inflammatory Nonscarring Alopecia Associated With the Tyrosine Kinase Inhibitor Nilotinib
A cancer drug called nilotinib might cause hair loss due to inflammation around hair follicles.
research Spironolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs
Spironolactone may make some cancer treatments more effective by blocking a protein that helps cancer cells survive.
research NF-κB in Biology and Targeted Therapy: New Insights and Translational Implications
NF-κB signaling is crucial in many diseases and can be targeted for new treatments.
research Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
Cancer treatments targeting specific cells and the immune system can cause skin, mouth, hair, and nail problems, affecting patients' quality of life and treatment adherence.
research Careless Talk Costs Lives: Fibroblast Growth Factor Receptor Signalling and the Consequences of Pathway Malfunction
Fibroblast growth factor receptor signaling controls cell development and repair, and its malfunction can cause disorders and cancer, but it also offers potential for targeted therapies.
research Drugs and Hair Loss: Mechanisms and Clinical Implications
Some medications can cause hair loss, but stopping the drug usually leads to recovery within 3 months.
research The Incidence and Management of Cutaneous Adverse Events of the Epidermal Growth Factor Receptor Inhibitors
EGFR inhibitors can cause various skin issues during cancer treatment, and managing these is important for patient care.
research Dermatologic Reactions to Targeted Therapy
Targeted cancer therapies can cause skin side effects, which should be treated early to help patients' quality of life and treatment adherence.
research Cutaneous Toxicities of New Targeted Cancer Therapies: Must Know for Diagnosis, Management, and Patient-Proxy Empowerment
New targeted cancer drugs can cause skin side effects, and managing them requires patient education and timely care.
research Reversing Gray Hair: Inspiring the Development of New Therapies Through Research on Hair Pigmentation and Repigmentation Progress
Gray hair can potentially be reversed, leading to new treatments.
research Epidermal Growth Factor Receptor Mutant T790M-L858R-V948R Inhibitor from Calophyllum Inophyllum L. Leaf as Potential Non-Small Cell Lung Cancer Drugs
A compound from Calophyllum inophyllum L. leaf may help treat non-small cell lung cancer.